import asyncio
import random

async def simulate_ai_generation(text: str) -> dict:
    """
    Simulates a high-quality AI engine converting a CSR document
    into the IMRaD research article format.
    """
    # Simulate processing delay for "thinking"
    await asyncio.sleep(2)
    
    # We will generate static, high-quality simulated content wrapped in typical
    # scientific phrasing, assuming the input text relates to a clinical study.
    
    # In a real implementation, we would pass `text` to an LLM like GPT-4 or Gemini 1.5 Pro.
    # Here, we return high-quality mock data for the hackathon POC.
    
    response = {
        "Abstract": (
            "Background: This study evaluated the efficacy and safety of the investigational compound "
            "in patients with the target indication. Methods: A randomized, double-blind, placebo-controlled "
            "phase 3 trial was conducted across 45 centers. Primary endpoint was the change from baseline at week 12. "
            "Results: A total of 450 subjects were randomized. The study met its primary endpoint with a statistically "
            "significant improvement compared to placebo (p < 0.001). Adverse events were mild to moderate. "
            "Conclusion: The compound demonstrated a favorable risk-benefit profile, supporting its clinical utility."
        ),
        "Introduction": (
            "The therapeutic landscape for this condition has evolved, yet significant unmet medical needs remain. "
            "Current standard-of-care treatments are often associated with suboptimal response rates and dose-limiting safety "
            "concerns. The investigational compound is a novel, highly selective inhibitor designed to target the underlying "
            "pathophysiology of the disease. Previous phase 1 and 2 studies established a preliminary proof-of-concept, "
            "demonstrating dose-dependent pharmacodynamic engagement and a manageable safety profile. This phase 3 study "
            "(protocol number: CSR-1004) was designed to definitively ascertain the efficacy and safety of the compound "
            "over a 12-week primary evaluation period, followed by an open-label extension."
        ),
        "Methods": (
            "Study Design: This was a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. "
            "Patients were randomized 1:1 to receive either the active investigational product (10 mg daily) or a matching "
            "placebo for 12 weeks. \n\n"
            "Key Inclusion Criteria: Adult patients aged 18 to 75 years with a confirmed diagnosis of the target condition "
            "for at least 6 months prior to screening. Patients must have had an inadequate response to at least one prior therapy. \n\n"
            "Statistical Analysis: Efficacy analyses were based on the intent-to-treat (ITT) population. The primary efficacy "
            "endpoint was analyzed using a mixed-effect model for repeated measures (MMRM). Safety was assessed in all randomized "
            "patients who received at least one dose of the study drug."
        ),
        "Results": (
            "Patient Disposition: Of the 500 patients screened, 450 were randomized (225 in each arm). Over 90% of patients "
            "in both arms completed the 12-week double-blind period. \n\n"
            "Efficacy: The primary endpoint, mean change from baseline to week 12 on the symptom severity scale, was -14.5 "
            "in the active group versus -4.2 in the placebo group. The least squares mean difference was -10.3 (95% CI: -12.4 to -8.2; p < 0.001). "
            "Secondary endpoints also showed statistically significant improvements, including a 40% higher response rate in the active "
            "arm (p < 0.01). \n\n"
            "Safety: Treatment-emergent adverse events (TEAEs) were reported in 65% of patients in the active arm and 60% in the "
            "placebo arm. The most common TEAEs were nausea, mild headache, and upper respiratory tract infections. Serious "
            "adverse events were rare and comparable between groups (2.2% vs 1.8%)."
        ),
        "Discussion": (
            "This phase 3 trial demonstrated that the investigational product significantly improved clinical outcomes in patients "
            "with the target condition. The robust efficacy across primary and secondary endpoints confirms the mechanistic "
            "rationale of targeting this specific pathway. \n\n"
            "The safety profile was consistent with earlier phase trials, with no new safety signals identified. The low rate of "
            "study discontinuation due to adverse events suggests the treatment is well-tolerated. \n\n"
            "Limitations of this study include the relatively short 12-week primary evaluation period. Long-term efficacy and "
            "durability of Response will be evaluated in the ongoing open-label extension. In conclusion, these findings support "
            "the potential of this compound as a newly viable therapeutic option for this patient population."
        )
    }
    
    return response
